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Introduction: First-line treatment with bevacizumab combined with
chemotherapy has been shown to improve outcomes in patients with
advanced, nonsquamous non-small cell lung cancer (NSNSCLC) in
phase III clinical trials. SAiL (MO19390), an open-label, multi-
center, single-arm study, evaluated the safety and efficacy of first-
line bevacizumab-based treatment in clinical practice. This report
presents the results of a preplanned subanalysis of Asian patients
enrolled in SAiL.
Methods: Patients with untreated, locally advanced, metastatic or
recurrent NSNSCLC received bevacizumab 7.5 or 15 mg/kg every 3
weeks plus chemotherapy for up to six cycles, followed by single-
agent bevacizumab until disease progression. Eligibility criteria for
SAiL permitted enrolment of a broad patient population. The pri-
mary end point was safety; secondary end points included time to
disease progression and overall survival.
Results: The Asian intent-to-treat population comprised 314 of the
2212 patients enrolled in the SAiL trial. In the Asian subanalysis,
patients received a median of nine cycles of bevacizumab, and the
median follow-up was 16.4 months. The incidence of clinically
significant adverse events (grade 3) of special interest was rela-
tively low in this population (15.6% overall); proteinuria (7.6%),
hypertension (4.8%), and bleeding (2.5%) were the most common.
A total of five adverse events related to bevacizumab were reported
as grade 5. Disease control rate was 94.1%, median time to disease
progression was 8.3 months, and median overall survival was 18.9
months.
Conclusions: The safety and efficacy of first-line bevacizumab-
based treatment in Asian patients with advanced NSNSCLC is
consistent with that demonstrated in phase III studies and in the
overall SAiL population. There were no new safety signals.
Key Words: Asian Continental Ancestry Group, Bevacizumab,
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(J Thorac Oncol. 2011;6: 1092–1097)
Lung cancer imposes a considerable public health andeconomic burden in Asian countries. In mainland China,
for example, the incidence of lung cancer has increased
rapidly over the past 2 decades, especially in females.1 In
2005, there were 497,908 new cases and 428,936 deaths in
China, the highest values for any malignancy.2 Ten-year
relative survival for lung cancer from the Singapore Cancer
Registry was 5.2% in men and 7.2% in women for the years
1998–2002, with only pancreas and liver cancers having
similar or lower survival rates.
Smoking rates and habits have a primary influence on
lung cancer incidence in Asian countries, and smoking rates
are ominously high, particularly among Asian men.3 Approx-
imately two-thirds of adult Chinese men are smokers,4 and
with smoking rates increasing and yet to peak in China and
other developing countries, deaths due to lung cancer are
expected to reflect this situation in the future. However, risk
factors for lung cancer vary among local population groups
and can include ambient urban air pollution as well as
occupational exposures such as cooking fumes. Finally, de-
spite the importance of smoking and environmental pollut-
ants, it is notable that never smokers with non-small cell lung
cancer are found disproportionately high in Asian patients,
particularly females with adenocarcinoma.
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With an urgent need for therapies that offer improved
outcomes and mitigate the burden of lung cancer, intensive
research efforts are aimed at developing novel treatment
strategies. Bevacizumab is a targeted antivascular endothelial
growth factor therapy that produces antitumor effects via
inhibition of angiogenesis and is indicated in several tumor
types, including nonsquamous non-small cell lung cancer
(NSNSCLC), metastatic colorectal cancer, metastatic breast
cancer, advanced and/or metastatic renal cell cancer, and
glioblastoma multiforme. The benefit of bevacizumab in
combination with standard platinum-based chemotherapy as
first-line treatment of unresectable, locally advanced, recur-
rent or metastatic NSNSCLC has been established in two
randomized phase III studies, the Eastern Cooperative Oncology
Group 4599 (E4599)5 and Avastin in Lung (AVAiL;
BO17704).6 In E4599, first-line bevacizumab in combination
with carboplatin/paclitaxel, followed by single-agent bevaci-
zumab until disease progression, increased the overall survival
(OS) in the overall population to 12.3 versus 10.3 months
achieved with chemotherapy alone (hazard ratio [HR]  0.79;
p  0.003). Median progression-free survival (PFS) was also
increased from 4.5 to 6.2 months with the addition of bevaci-
zumab (HR  0.66; p  0.001). In the AVAiL trial, PFS was
significantly prolonged in the patient population receiving bev-
acizumab-based therapy compared with chemotherapy alone
(median PFS, 6.7 versus 6.1 months; HR  0.75; p  0.003 in
the 7.5 mg/kg bevacizumab group and 0.65 versus 6.1 months;
HR 0.82; p 0.03 in the 15 mg/kg bevacizumab group). The
median OS in AVAiL was longer than 13 months in all treat-
ment groups, the improvement with the addition of bevacizumab
was not statistically significant compared with chemotherapy
alone (7.5 mg/kg group: HR  0.93; p  0.420; 15 mg/kg
group: HR  1.03; p  0.761).
Thus far, cost and risk benefit are controversial issues
around the use of bevacizumab in daily practice. Although
there are several economic analyses in a number of countries
that evaluate the costs of NSCLC treatments,7 only a few are
available for novel targeted therapies such as bevacizumab.
Several recent publications have reported the findings of
analyses on the cost-effectiveness of first-line treatment with
bevacizumab plus cisplatin and gemcitabine compared with
pemetrexed plus cisplatin from Italy and Germany in ad-
vanced NSNSCLC, with the direct costs for drug acquisition
and administration taken into account. The clinical benefits
with bevacizumab appeared to be achieved at a lower
monthly cost than the chemotherapy doublet regimen for
these patient populations. However, as with any study, one
must bear in mind the limitations of the analysis, the principal
one being the lack of direct comparisons between treatment
regimens.8,9
The recently completed SAiL trial (MO19390) aimed
to provide further data on the safety and efficacy of bevaci-
zumab combined with a range of standard first-line chemo-
therapy regimens in a broad patient population with advanced
or recurrent NSNSCLC, reflecting clinical practice in the
community setting. In the overall SAiL cohort (n  2212),
the incidence of grade 3 or higher adverse events (AEs) of
special interest was low (3.6%, 5.7%, and 3.0% for bleeding,
hypertension, and proteinuria, respectively), and bevaci-
zumab regimens produced highly favorable outcomes, as
reflected in disease control rate (DCR; 88.7%), median time
to disease progression (TTP; 7.8 months), and median OS
(14.6 months).10
Knowing that the response to targeted therapies may
vary among ethnic populations,11–14 we report the results of a
preplanned analysis of SAiL data for Asian patients (from the
source countries China, Taiwan, and Hong Kong). Findings
from this analysis will be placed in context with those of
phase III studies conducted primarily in Caucasian popula-
tions with advanced NSNSCLC (E4599 and AVAiL).
PATIENTS AND METHODS
Study Objectives
The primary objective of this preplanned subanalysis of
the SAiL study was to evaluate the safety profile of bevaci-
zumab when combined with chemotherapy in the first-line
treatment of patients of Asian origin with locally advanced,
recurrent or metastatic NSNSCLC. Secondary objectives
were to evaluate the efficacy of bevacizumab, in terms of
TTP and OS, and to assess the safety of bevacizumab com-
binations in patients developing central nervous system
(CNS) metastases.
Patient Population
The Asian subpopulation included patients recruited
from centers in China (nine sites), Hong Kong (six sites), and
Taiwan (five sites). Key inclusion criteria were histologically
or cytologically documented, inoperable, locally advanced
(stage IIIB with supraclavicular lymph node metastases or
malignant pleural or pericardial effusion), metastatic (stage
IV) or recurrent NSNSCLC; Eastern Cooperative Oncology
Group (ECOG) performance status (PS) 0 to 2; life expec-
tancy 3 months; and adequate hematological, hepatic, and
renal function. Patients recruited from China had to have
ECOG PS 0 to 1. Key exclusion criteria included mixed,
non-small cell, and small cell tumors or mixed adenosqua-
mous carcinomas with a predominant squamous component;
history of hemoptysis (2.5 ml red blood per episode) within
3 months before enrolment; radiological evidence of tumor
invading or abutting major blood vessels; evidence of CNS
metastases (even if previously treated); neoadjuvant or adju-
vant chemotherapy within 6 months before enrolment; major
surgery within 28 days before enrolment; uncontrolled hy-
pertension, thrombotic, or hemorrhagic disorders; and radio-
therapy with curative intent within 28 days before enrolment.
Patients on full-dose anticoagulation were also excluded.
Study Design and Treatment
Eligible patients received bevacizumab at a dose of
either 7.5 or 15 mg/kg every 3 weeks (at the investigator’s
discretion) for up to six cycles, in combination with standard
first-line chemotherapy (selected at the investigator’s discre-
tion). In the absence of disease progression, patients contin-
ued to receive single-agent bevacizumab treatment until the
development of progression or unacceptable toxicity. Patients
recruited from China received bevacizumab at a dose of 15
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mg/kg combined with carboplatin (AUC 6 every 3 weeks)
and paclitaxel (175 mg/m2 every 3 weeks).
Safety Analysis
The safety profile of first-line bevacizumab combined
with chemotherapy was assessed from incidence data for all
reported serious AEs (SAEs) and non-SAEs. The incidence
of several AEs of special interest was also noted: hyperten-
sion, proteinuria, wound healing complications, gastrointes-
tinal perforations, arterial and venous thromboembolic
events, hemoptysis, CNS bleeding, other hemorrhages, and
congestive heart failure.
National Cancer Institute Common Terminology Crite-
ria for Adverse Events version 3.0 was used to classify the
severity of AEs. All AE data were recorded up to 28 days
after the last bevacizumab infusion, whereas AEs of special
interest were reported up to 6 months after the last bevaci-
zumab dose. Bevacizumab-associated SAEs were reported
for the duration of the study.
Efficacy Analysis
Duration of survival was defined as the time period
from the start of first-line therapy to death. Where the date of
death was missing, the most recent date at which the patient
was known to be alive was used. Patients with no death
recorded at the time of analysis were censored at the most
recent date that they were known to be alive. Tumor assess-
ments were performed according to the treating physicians’
clinical practice; no specific evaluation method or frequency
was protocol-mandated, and no centralized independent eval-
uation was conducted.
TTP was defined as the time period from the start of
first-line therapy to investigator-assessed disease progression.
Where the date of progressive disease (PD) was missing, the
date of the respective visit was used. Patients who had not
progressed at the time of the analysis, including patients who
died before PD, were censored at the date of last bevaci-
zumab administration. Information on treatment used after
disease progression was not collected.
This report presents data for the efficacy and safety of
first-line bevacizumab-based therapy in Asian patients en-
rolled in SAiL, with a final date for inclusion of July 24,
2009.
Statistical Analysis
This primary population for this subanalysis was the
subset of the intent-to-treat (ITT) population of SAiL enrolled
from China, Hong Kong, and Taiwan with at least one valid
postbaseline assessment. Statistical methods were those used
in the overall SAiL population analyses; analyses of demo-
graphics, baseline characteristics, safety, and efficacy were
based on this population. Estimated 95% confidence intervals
(CIs) and event rates were calculated. The incidence of
infrequent (1%) SAEs were estimated within approxi-
mately 0.4% to 0.5% (for the overall study population),
and the incidence of uncommon SAEs was estimated to
within approximately 1.7% to 2.3% (for any subpopula-
tion of 500 patients). SAEs were summarized by incidence
rates and 95% Pearson-Clopper CIs. Incidence rates and 95%
Pearson-Clopper CIs were also produced for AEs of special
interest, including all events regardless of severity or rela-
tionship to bevacizumab treatment.
RESULTS
Patients and Treatments
The ITT population in this analysis comprised 314
patients of Asian ethnicity, recruited from China (n  197),
Hong Kong (n  55), and Taiwan (n  62) between August
2006 and June 2008. Demographic data for the study popu-
lation are summarized in Table 1. Patients had a mean age of
55.5 years, 56.4% were male, and approximately one-half
were current or former smokers. The majority of patients
(70.7%) had stage IV disease at entry, and 69.1% had an
ECOG PS of 1. Among those with tumor sampling (97.8%),
adenocarcinoma was present in 95.1%. A total of 153 patients
(48.7%) were receiving medications at baseline, with 50
(15.9%) receiving cardiovascular medication, 66 (21.0%)
receiving analgesics, 70 (22.3%) being treated for hyperten-
TABLE 1. Summary of Demographic and Baseline
Characteristics for the SAiL Asian Population
Parameter
SAiL Asian Population
(n  314)
Age, yr, mean (range) 55.5 (25–78)
Male, n (%) 177 (56.4)
ECOG PS, n (%)
0 88 (28.0)
1 217 (69.1)
2 9 (2.9)
Smoking status, n (%)
Never 161 (51.3)
Former 122 (38.9)
Current 31 (9.9)
Stage, n (%)
IIIb 92 (29.3)
IV 222 (70.7)
Metastatic site, n (%)a
Bone 96 (43.0)
Lung 149 (66.8)
Liver 22 (9.9)
Other 57 (25.6)
Pathology, n (%)b
Adenocarcinoma 292 (95.1)
Bronchoalveolar carcinoma 4 (1.3)
Large cell carcinoma 1 (0.3)
Other 10 (3.3)
Centrally located lung cancer, n (%) 67 (21.3)
Tumor cavitated, n (%) 10 (3.2)
Receiving baseline medication, n (%)
Cardiovascular 50 (15.9)
Analgesics 66 (21.0)
Anticoagulants (prophylactic) 1 (0.3)
a Percentages based on patients with metastatic disease; multiple entries were
possible.
b Percentages based on patients with tumor samples taken (97.8% of total).
ECOG PS, Eastern Cooperative Oncology Group performance status.
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sion, and a single patient receiving prophylactic anticoagulant
treatment.
Patients received bevacizumab at a dose of 15 mg/kg
(n  310; 98.7%) or 7.5 mg/kg (n  4; 1.3%). Patients
received a median of nine cycles of bevacizumab (range,
1–38) and six cycles of chemotherapy (range, 1–9), and the
median duration of follow-up in this population was 16.4
months. The median duration of bevacizumab treatment was
27.3 weeks and that of chemotherapy was 15.1 weeks. The
number of cycles of bevacizumab received was between 1
and4 in 43 patients (13.7%), 4 and7 in 59 (18.8%), 7 and
10 in 61 patients (19.4%), and 10 in 151 (48.1%).
Bevacizumab was most commonly combined with carbopla-
tin doublet chemotherapy regimens (76.1%) and more spe-
cifically carboplatin/paclitaxel (63.7%). Cisplatin doublets
were administered to 18.8% of patients and in nearly all cases
cisplatin was combined with gemcitabine (18.2%). Mono-
therapy regimens were administered to 0.6% of the popula-
tion, and 4.5% of patients switched chemotherapy regimens
during the study.
Safety and Tolerability
AEs of special interest (all grades) were reported in
74.8% of patients, the most common being proteinuria, hy-
pertension, and bleeding (Table 2). Ninety-two SAEs oc-
curred in 61 patients (19.4%), of which 17 in 15 patients
(4.8%) were deemed by investigators to be related to bevaci-
zumab treatment. However, the incidence of clinically sig-
nificant (grade 3) AEs of special interest was only 15.6%.
The most common clinically significant AEs of special inter-
est were proteinuria (experienced by 7.6% of patients) and
hypertension (experienced by 4.8% of patients).
Despite 43 patients developing CNS metastases during
study treatment, only three (grade 1) CNS bleeding events
were reported. There were no instances of grade 3 wound
healing complications, and congestive heart failure was not
observed during the study. Five grade 5 AEs were reported:
hemoptysis, pulmonary embolism, cerebral infarction, lacu-
nar infarction, and acute hepatitis. Most (76.6%) of AEs of
special interest resolved or improved during the study (Table
TABLE 2. Incidence of Adverse Events of Special Interest According to CTC Grade in the SAiL
Asian Population
SAiL Asian Population (n  314)
All Grades Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Grade >3
Bleeding 49.7 44.3 7.6 2.2 0 0.3 2.5
Epistaxis 36.9 34.1 3.2 1.0 0 0 1.0
Pulmonary hemorrhagea 13.4 10.8 1.9 0.3 0 0.3 0.6
CNS bleedingb 1.0 1.0 0 0 0 0 0
Other bleeding 14.0 11.5 2.5 1.0 0 0 1.0
Hypertension 29.3 12.7 16.2 4.8 0 0 4.8
Proteinuria 40.4 17.8 22.0 6.4 1.3 0 7.6
Thromboembolic events 3.2 0.3 1.0 0.6 1.0 1.9 2.2
Gastrointestinal perforation 0.6 0 0 0.3 0.3 0 0.6
Wound healing complications 0.6 0.3 0.3 0 0 0 0
Values are given as percentage of patients.
a Pulmonary hemorrhage/hemoptysis.
b Cerebral hemorrhage/hematoma.
CTC, common toxicity criteria; CNS, central nervous system.
TABLE 3. Adverse Events (AEs) of Special Interest by Outcome and Action Taken (Based on Total of 649 AEs in the Asian
Population; n  314)
AEs, n (%)a
Outcome
Action Taken
Resolved Improved Persistent Led to Death
Temporarily
Interrupted
Permanently
Discontinued
Any AE (n  649) 433 (66.7) 64 (9.9) 148 (22.8) 4 (0.6) 28 (4.3) 32 (4.9)
Bleeding (n  299) 258 (86.3) 13 (4.3) 27 (9.0) 1 (0.3) 3 (1.0) 17 (5.7)
Hypertension (n  126) 61 (48.4) 18 (14.3) 47 (37.3) 0 (0.0) 15 (11.9) 2 (1.6)
Proteinuria (n  208) 109 (52.4) 29 (13.9) 70 (33.7) 0 (0.0) 9 (4.3) 5 (2.4)
Thromboembolism (n  12) 2 (16.7) 3 (25.0) 4 (33.3) 3 (25.0) 1 (8.3) 6 (50.0)
Gastrointestinal perforation (n  2) 1 (50.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0)
Wound healing complications (n  2) 2 (100) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total number of AEs  649.
a Percentages are based on total number of AEs within each AE category.
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3). Interruption or permanent discontinuation of bevacizumab
administration because of AEs of special interest was an
infrequent occurrence (9.2%; Table 3).
Clinical Efficacy
Efficacy was evaluable in 305 of the 314 patients in the
ITT population (97.1%). In these patients, the overall re-
sponse rate was 57.7% and the DCR was 94.1% (Figure 1).
At the final efficacy analysis of the ITT population, 241
patients (76.8%) had experienced PD; 73 patients had not
progressed or had died before PD and were censored. The
median TTP determined by Kaplan-Meier analysis was 8.3
months (95% CI: 7.7–8.8) at a median follow-up of 16.4
months (Figure 2). During the period for which data were
analyzed, 162 patients (51.6% of the ITT population) died,
153 (94.4%) of them from lung cancer. Median OS was 18.9
months (95% CI: 17.4–20.7), based on 152 censored patients.
DISCUSSION
The SAiL trial, a multicenter single-arm investigation
involving 400 centers worldwide, assessed the safety and
efficacy profile of first-line bevacizumab therapy in a broad
population of more than 2000 patients with advanced
NSNSCLC.10 The results from a preplanned subanalysis of
Asian patients are consistent with those of the overall SAiL
population.
The safety analysis of the global SAiL population
showed a generally low incidence of grade3 AEs of special
interest to bevacizumab, such as bleeding (3.6%), hyperten-
sion (5.7%), proteinuria (3.0%), thromboembolism (7.8%),
congestive heart failure (0.5%), and gastrointestinal perfora-
tion (1.2%). The comparative rates for these grade3 AEs in
the SAiL Asian population were similarly low: 2.5%, 4.8%,
7.6%, 2.2%, 0%, and 0.6%, respectively, and no new safety
signals related to bevacizumab were reported in this popula-
tion. The above rates for the SAiL Asian subpopulation were
also consistent with those reported in phase III, randomized,
controlled trials of bevacizumab combined with chemother-
apy in advanced NSNSCLC (E45995 and AVAiL6) and with
the phase II Japanese trial JO19907.10
Efficacy data from this subanalysis, albeit positive,
should be interpreted with caution, given that SAiL was a
single-arm study and the tumor assessments were performed
according to the physicians’ clinical practice (DCR of 94.1%,
median TTP of 8.3 months, and median OS of 18.9 months
for bevacizumab-treated patients). In the overall SAiL pop-
ulation, DCR was 89%, the median TTP was 7.8 months, and
the median OS was 14.6 months.10 In bevacizumab-treated
patients in the E4599 trial, median PFS was 6.2 months, and
in AVAiL, it was 6.7 and 6.5 months,12 for the 7.5 and 15
mg/kg bevacizumab groups, respectively. Median OS was
longer than a year in both E4599 and AVAiL (E4599: 12.3
months5; AVAiL: 13.6 and 13.4 months15 for the 7.5 and 15
mg/kg groups, respectively). Patients with adenocarcinoma
histology in E4599 reached a median OS of 14.2 months.16
A post hoc analysis of efficacy data from a small cohort
(n  105) of Asian patients in AVAiL supports an enhanced
benefit in this subgroup compared with the overall study
population (unpublished observation). Bevacizumab 7.5 and
15 mg/kg versus chemotherapy alone prolonged PFS to 8.8
months (HR 0.49) and 8.7 months (HR 0.61 versus 6.1
months) and increased overall response rate (47% and 41%
versus 15%) and median OS (28 months [HR 0.46] and 26
months [HR 0.79] versus 17.4 months), respectively. In
addition, a randomized study of 180 Japanese patients with
FIGURE 1. Efficacy outcomes based on tumor assessment
in the SAiL Asian population (n  305).
FIGURE 2. Median time to disease progression (a) and median overall survival (b) in the SAiL Asian population.
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advanced NSNSCLC (JO19907) demonstrated that the addi-
tion of bevacizumab to carboplatin doublet therapy signifi-
cantly prolonged median PFS (6.9 versus 5.9 months; p 
0.009) and substantially increased overall response rate (61%
versus 31%; p  0.0013) and DCR (94% versus 71%; p 
0.0002), compared with chemotherapy alone.14
Efficacy data for bevacizumab in Asian patients suggest
an enhanced benefit in this NSNSCLC subpopulation com-
pared with data from trials conducted in mainly Caucasian
populations; the same is noted for clinical trials involving
chemotherapy17 or epidermal growth factor receptor tyrosine
kinase inhibitors (regardless of epidermal growth factor re-
ceptor mutational status).12–21 It is also worth noting that, for
reasons that remain uncertain, adenocarcinoma histology ap-
pears to be more treatment-responsive and its incidence in
Chinese patients is among the highest worldwide.18 Asian
patients in SAiL had a greater proportion of never smokers
(51% versus 30%) and patients who had adenocarcinoma
histology (95% versus 86%) compared with the overall SAiL
study group. Although these demographic factors might have
contributed to a better outcome, the higher number of Asian
patients receiving cardiovascular medication (32% versus
16%) and having a worse ECOG PS profile (ECOG PS 1:
69.1% versus 56.6%) would suggest that there was no bias
toward an overall better performing population.
The main limitation of the Asian subanalysis of the
SAiL trial is the relatively small number of patients, which
reduces the robustness of the study data and does not allow
for the reporting of certain key data such as use of bevaci-
zumab with a range of chemotherapy regimens. As noted in
the overall SAiL results,10 the effects of subsequent lines of
therapy could not be determined, as these data were not
collected. This may have had a confounding effect on the
apparent benefit of bevacizumab-based treatment. Clearly,
the lack of any control group is also a limitation, although this
is a reflection of the clinical setting of a study that aimed to
evaluate bevacizumab in everyday oncological practice.
In summary, the safety and efficacy of first-line bev-
acizumab in combination with chemotherapy was confirmed
in this preplanned subanalysis of Asian patients with ad-
vanced NSNSCLC enrolled in the SAiL study. In evaluating
patients typically seen in clinical practice in the community
setting, the SAiL study builds on the experience gained in
earlier trials of bevacizumab in more selected groups of
patients with NSNSCLC. The findings of this report are
consistent with those of the global SAiL population and phase
III trials of bevacizumab in this setting. No new safety
concerns were identified in the Asian population.
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